IP Library Granted Patent US 11,261,213
Granted Patent B2
US 11,261,213 · App. 16/866,054 · Granted Mar 1, 2022

Crystalline bis- and tris-hydrochloride salt of elamipretide

Inventor: Scott M. Duncan (Bedford, MA)
Assignee: Stealth BioTherapeutics Inc.
C07K5/1019C07K1/14C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,261,213
App. No.
16/866,054
Granted
Mar 1, 2022
Kind
B2
Abstract

Disclosed are crystalline forms of the bis- and tris-(hydrochloride) salts of D-Arg-Tyr(2,6-DiMe)-Lys-Phe-NH 2 , which is also known as MTP-131.

Claims (8)

1. A process for making a pharmaceutical composition comprising Compound (I),

comprising dissolving a crystalline form of a bis-(hydrochloride) salt of Compound (I);

wherein said crystalline form has peaks in its XRPD pattern at values of two theta (° 2θ) of: 6.4, 9.8, 13.1, 16.9, 19.1, and 29.7.

2. The process of claim 1 , wherein said crystalline form has peaks in its XRPD pattern at values of two theta (°2θ) of: 6.4, 7.0, 7.9, 9.1, 9.8, 10.2, 11.7, 13.1, 16.9, 19.1, 20.6, 24.2, 24.8, 26.3, 27.4, 28.6, and 29.7.

3. A process for making a pharmaceutical composition comprising Compound (I),

comprising dissolving a crystalline form of a tris-(hydrochloride) salt of Compound (I);

wherein said crystalline form has peaks in its XRPD pattern at values of two theta (° 2θ) of: 8.1, 11.5, 15.6, 15.9, 22.1, 23.0, and 27.4.

4. The process of claim 3 , wherein said crystalline form has peaks in its XRPD pattern at values of two theta (° 2θ) of: 8.1, 9.8, 11.0, 11.5, 12.4, 14.9, 15.6, 15.9, 20.1, 21.8, 22.1, 23.0, 27.4, and 28.0.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2021
From: STEALTH BIOTHERAPEUTICS CORP.
To: STEALTH BIOTHERAPEUTICS INC.
Reel/Frame 058601/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2021
From: DUNCAN, SCOTT M.
To: STEALTH BIOTHERAPEUTICS CORP.
Reel/Frame 056126/0159 →
Continuity (4)
Continuation 16259575 · Jan 28, 2019
Provisional Application 62656649 · Apr 12, 2018
Provisional Application 62622259 · Jan 26, 2018
Related Publication 20210061853A1 · Mar 4, 2021
Cited By (1)
US 12,252,553